Enhancement of antibody functions through Fc multiplications

• Published in: mAbs 2017-04, Vol.9 (3), p.393-403
• Main Authors: Wang, Qun, Chen, Yan, Pelletier, Mark, Cvitkovic, Romana, Bonnell, Jessica, Chang, Chien-Ying, Koksal, Adem C, O'Connor, Ellen, Gao, Xizhe, Yu, Xiang-Qing, Wu, Herren, Stover, C Kendall, Dall'Acqua, William F, Xiao, Xiaodong
• Format: Article
• Language: English
• Subjects: Animals; Immunoglobulin Fc Fragments - chemistry; Immunoglobulin Fc Fragments - immunology; Immunoglobulin Fc Fragments - pharmacology; Immunoglobulin G - chemistry; Immunoglobulin G - immunology; Immunoglobulin G - pharmacology; Klebsiella Infections - immunology; Klebsiella pneumoniae; Mice; Mice, Inbred C57BL; Protein Engineering - methods
• ISSN: 1942-0862; 1942-0870
• DOI: 10.1080/19420862.2017.1281505

Antibodies carry out a plethora of functions through their crystallizable fragment (Fc) regions, which can be naturally tuned by the adoption of several isotypes and post-translational modifications. Protein engineering enables further Fc function modulations through modifications of the interactions between the Fc and its functional partners, including FcγR, FcRn, complement complex, and additions of auxiliary functional units. Due to the many functions embedded within the confinement of an Fc, a suitable balance must be maintained for a therapeutic antibody to be effective and safe. The outcome of any Fc engineering depends on the interplay among all the effector molecules involved. In this report, we assessed the effects of Fc multiplication (or tandem Fc) on antibody functions. Using IgG1 as a test case, we found that, depending on the specifically designed linker, Fc multiplication led to differentially folded, stable molecules with unique pharmacokinetic profiles. Interestingly, the variants with 3 copies of Fc improved in vitro opsonophagocytic killing activity and displayed significantly improved protective efficacies in a Klebsiella pneumoniae mouse therapeutic model despite faster clearance compared with its IgG1 counterpart. There was no adverse effect observed or pro-inflammatory cytokine release when the Fc variants were administered to animals. We further elucidated that enhanced binding to various effector molecules by IgG-3Fc created a "sink" leading to the rapid clearance of the 3Fc variants, and identified the increased FcRn binding as one strategy to facilitate "sink" escape. These findings reveal new opportunities for novel Fc engineering to further expand our abilities to manipulate and improve antibody therapeutics.